Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
NEUROLOGIX INC (NRGX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2011 |
8-K
| Quarterly results|
Docs:
|
"NEUROLOGIX, INC. BALANCE SHEETS June 30, 2011 December 31, 2010 ASSETS Current assets: Cash and cash equivalents $ 3,453 $ 8,055 Prepaid expenses and other current assets 319 481 Total current assets 3,772 8,536 Equipment, less accumulated depreciation of $704 and $682 at June 30, 2011 and December 31, 2010, respectively 49 71 Intangible assets, less accumulated amortization of $426 and $364 at June 30, 2011 and December 31, 2010, respectively 1,137 1,065 Other assets 5 5 Total assets $ 4,963 $ 9,677 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable and accrued expenses $ 3,375 $ 2,302 Notes payable, net of discount 6,078 4,695 Total current liabilities 9,453 6,997 Derivative financial instruments, at estimated fair value – warrants 4,174 6,840 Total liabilities $..." |
|
| 05/13/2011 |
8-K
| Quarterly results |
| 03/25/2011 |
8-K
| Form 8-K - Current report |
| 08/12/2010 |
8-K
| Form 8-K - Current report |
| 05/13/2010 |
8-K
| Quarterly results |
| 03/26/2010 |
8-K
| Form 8-K - Current report |
| 11/12/2009 |
8-K
| Quarterly results |
| 08/12/2009 |
8-K
| Form 8-K -- Current report |
| 05/12/2009 |
8-K
| Form 8-K -- Current report |
| 03/26/2009 |
8-K
| Form 8-K -- Current report |
| 11/14/2008 |
8-K
| Quarterly results|
Docs:
|
"Cautionary Statement Regarding Forward-looking Statements This news release includes certain statements of the Company that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements ..." |
|
| 08/12/2008 |
8-K
| Quarterly results|
Docs:
|
"NEUROLOGIX ANNOUNCES SECOND QUARTER 2008 FINANCIAL RESULTS FORT LEE, N.J. Neurologix, Inc. , a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today its financial results for the second quarter and six months ended June 30, 2008. For the three months ended June 30, 2008, the Company reported a net loss of $1.4 million, as compared with a net loss of $1.9 million for the three months ended June 30, 2007. The Company reported a net loss applicable to common stock for the second quarter of 2008 of $2.8 million, or $0.10 per basic and diluted share, as compared with a net loss applicable to common stock of $2.2 million, or $0.08 per share, for the same period in 2007. The net loss applicable to common stock inclu..." |
|
| 05/12/2008 |
8-K
| Quarterly results|
Docs:
|
"NEUROLOGIX ANNOUNCES FIRST QUARTER 2008 FINANCIAL RESULTS FORT LEE, N.J. Neurologix, Inc. , a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today its financial results for the first quarter ended March 31, 2008. For the three months ended March 31, 2008, the Company reported a net loss of $1.8 million, as compared with a net loss of $1.5 million for the first quarter of 2007. The Company reported a net loss applicable to common stock for the three months ended March 31, 2008 of $2.4 million, or $0.09 per basic and diluted share, as compared with a net loss applicable to common stock of $1.8 million, or $0.07 per basic and diluted share, for the same period in 2007. The net loss applicable to common stock in..." |
|
| 03/26/2008 |
8-K
| Quarterly results|
Docs:
|
"Neurologix Announces Year End 2007 Results Fort Lee, New Jersey ― Neurologix, Inc. , a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, today announced its financial results for the year ended December 31, 2007. For the year ended December 31, 2007, the Company reported a net loss of $6.8 million, as compared with a net loss of $7.0 million for the year ended December 31, 2006. The Company reported a net loss applicable to common stock for the year ended December 31, 2007 of $13.8 million, or $0.51 per basic and diluted share, as compared with a net loss applicable to common stock for the year ended December 31, 2006 of $10.4 million, or $0.39 per basic and diluted share, for the same period in 2006. The net loss ..." |
|
| 11/09/2007 |
8-K
| Quarterly results |
| 08/15/2007 |
8-K
| Quarterly results |
| 05/14/2007 |
8-K
| Quarterly results|
Docs:
|
"NEUROLOGIX ANNOUNCES FIRST QUARTER 2007 RESULTS ________________________________________________ FORT LEE, N.J. Neurologix, Inc. , a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today its financial results for the first quarter ended March 31, 2007. For the three months ended March 31, 2007, the Company reported a net loss of $1.5 million, as compared with a net loss of $1.5 million for the first quarter of 2006. The Company reported a net loss applicable to common stock for the three months ended March 31, 2007 of $1.8 million, or $0.07 per basic and diluted shares, as compared with $1.5 million, or $0.06 per basic and diluted share, for the same period in 2006. The net loss applicable to common stock for..." |
|
| 04/03/2007 |
8-K
| Quarterly results |
| 11/14/2006 |
8-K
| Quarterly results |
|
|